Suppr超能文献

Ctr1和Ctr2在哺乳动物铜稳态及铂类化疗中的作用。

The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.

作者信息

Öhrvik Helena, Thiele Dennis J

机构信息

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.

出版信息

J Trace Elem Med Biol. 2015;31:178-82. doi: 10.1016/j.jtemb.2014.03.006. Epub 2014 Mar 24.

Abstract

Copper (Cu) is an essential metal for growth and development that has the potential to be toxic if levels accumulate beyond the ability of cells to homeostatically balance uptake with detoxification. One system for Cu acquisition is the integral membrane Cu(+) transporter, Ctr1, which has been quite well characterized in terms of its function and physiology. The mammalian Ctr2 protein has been a conundrum for the copper field, as it is structurally closely related to the high affinity Cu transporter Ctr1, sharing important motifs for Cu transport activity. However, in contrast to mammalian Ctr1, Ctr2 fails to suppress the Cu-dependent growth phenotype of yeast cells defective in Cu(+) import, nor does it appreciably stimulate Cu acquisition when over-expressed in mammalian cells, underscoring important functional dissimilarities between the two proteins. Several roles for the mammalian Ctr2 have been suggested both in vitro and in vivo. Here, we summarize and discuss current insights into the Ctr2 protein and its interaction with Ctr1, its functions in mammalian Cu homeostasis and platinum-based chemotherapy.

摘要

铜(Cu)是生长发育所必需的金属,如果其含量积累超过细胞将摄取与解毒进行稳态平衡的能力,就可能具有毒性。一种获取铜的系统是整合膜铜离子转运蛋白Ctr1,其功能和生理学特性已得到相当充分的表征。哺乳动物的Ctr2蛋白一直是铜领域的一个难题,因为它在结构上与高亲和力铜转运蛋白Ctr1密切相关,共享铜转运活性的重要基序。然而,与哺乳动物的Ctr1不同,Ctr2不能抑制铜离子导入缺陷的酵母细胞的铜依赖性生长表型,在哺乳动物细胞中过表达时也不会明显刺激铜的摄取,这突出了这两种蛋白之间重要的功能差异。在体外和体内都提出了哺乳动物Ctr2的几种作用。在这里,我们总结并讨论了目前对Ctr2蛋白及其与Ctr1相互作用、在哺乳动物铜稳态和铂类化疗中的功能的见解。

相似文献

1
The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.
J Trace Elem Med Biol. 2015;31:178-82. doi: 10.1016/j.jtemb.2014.03.006. Epub 2014 Mar 24.
2
3
Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain.
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):E4279-88. doi: 10.1073/pnas.1311749110. Epub 2013 Oct 28.
4
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
Metallomics. 2014 Mar;6(3):654-61. doi: 10.1039/c3mt00331k. Epub 2014 Feb 13.
5
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Clin Cancer Res. 2009 Jul 1;15(13):4312-21. doi: 10.1158/1078-0432.CCR-09-0311. Epub 2009 Jun 9.
6
The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).
Metallomics. 2015 Nov;7(11):1477-87. doi: 10.1039/c5mt00131e. Epub 2015 Jul 24.
8
Reconstitution of a thermophilic Cu importer reveals intrinsic high-affinity slow transport driving accumulation of an essential metal ion.
J Biol Chem. 2018 Oct 5;293(40):15497-15512. doi: 10.1074/jbc.RA118.004802. Epub 2018 Aug 21.
9
Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter.
J Biol Chem. 2004 Dec 24;279(52):54221-9. doi: 10.1074/jbc.M411669200. Epub 2004 Oct 19.
10
Identification of a vacuole-associated metalloreductase and its role in Ctr2-mediated intracellular copper mobilization.
J Biol Chem. 2007 Jul 27;282(30):21629-38. doi: 10.1074/jbc.M703397200. Epub 2007 Jun 6.

引用本文的文献

1
Cuproptosis-related genes and agents: implications in tumor drug resistance and future perspectives.
Front Pharmacol. 2025 May 8;16:1559236. doi: 10.3389/fphar.2025.1559236. eCollection 2025.
2
Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis.
Cancer Drug Resist. 2025 Mar 26;8:15. doi: 10.20517/cdr.2025.41. eCollection 2025.
5
Mitochondrial copper overload promotes renal fibrosis via inhibiting pyruvate dehydrogenase activity.
Cell Mol Life Sci. 2024 Aug 9;81(1):340. doi: 10.1007/s00018-024-05358-1.
7
Copper in colorectal cancer: From copper-related mechanisms to clinical cancer therapies.
Clin Transl Med. 2024 Jun;14(6):e1724. doi: 10.1002/ctm2.1724.
8
Molecular Regulatory Mechanism of Nano-Se Against Copper-Induced Spermatogenesis Disorder.
Biol Trace Elem Res. 2025 Jan;203(1):249-260. doi: 10.1007/s12011-024-04153-0. Epub 2024 Mar 26.
9
A nanocomposite competent to overcome cascade drug resistance in ovarian cancer mitochondria dysfunction and NO gas synergistic therapy.
Asian J Pharm Sci. 2023 Nov;18(6):100872. doi: 10.1016/j.ajps.2023.100872. Epub 2023 Nov 30.
10
Abnormalities in Copper Status Associated with an Elevated Risk of Parkinson's Phenotype Development.
Antioxidants (Basel). 2023 Aug 22;12(9):1654. doi: 10.3390/antiox12091654.

本文引用的文献

1
Cellular distribution of copper to superoxide dismutase involves scaffolding by membranes.
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20491-6. doi: 10.1073/pnas.1309820110. Epub 2013 Dec 2.
2
Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain.
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):E4279-88. doi: 10.1073/pnas.1311749110. Epub 2013 Oct 28.
3
Atox1 contains positive residues that mediate membrane association and aid subsequent copper loading.
J Membr Biol. 2013 Dec;246(12):903-13. doi: 10.1007/s00232-013-9592-1. Epub 2013 Sep 15.
4
Kinetics and thermodynamics of metal binding to the N-terminus of a human copper transporter, hCTR1.
Chem Commun (Camb). 2013 Oct 14;49(80):9134-6. doi: 10.1039/c3cc45360j. Epub 2013 Aug 21.
6
SLC31 (CTR) family of copper transporters in health and disease.
Mol Aspects Med. 2013 Apr-Jun;34(2-3):561-70. doi: 10.1016/j.mam.2012.07.011.
7
Structure and function of copper uptake transporters.
Curr Top Membr. 2012;69:97-112. doi: 10.1016/B978-0-12-394390-3.00004-5.
9
Charting the travels of copper in eukaryotes from yeast to mammals.
Biochim Biophys Acta. 2012 Sep;1823(9):1580-93. doi: 10.1016/j.bbamcr.2012.02.011. Epub 2012 Feb 24.
10
Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.
Gynecol Oncol. 2011 Aug;122(2):361-5. doi: 10.1016/j.ygyno.2011.04.025. Epub 2011 May 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验